Today: 19 March 2026
Subscribe
Browse Category

NYSE:UMC 22 June 2025 - 8 February 2026

UMC stock price: United Microelectronics heads into Monday after AI capex talk sparks chip rebound

UMC stock price: United Microelectronics heads into Monday after AI capex talk sparks chip rebound

UMC’s U.S.-listed shares closed Friday at $10.06, up 0.9%, after Amazon and Alphabet signaled higher AI infrastructure spending. The Philadelphia semiconductor index jumped 5.7% and Nvidia gained 7.8%. UMC’s Taipei shares ended at NT$61.90. Investors await U.S. inflation and jobs data on Feb. 13 and UMC’s next sales update on March 5.
8 February 2026
········
UMC stock slides into Monday: what to watch as Taiwan trading reopens

UMC stock slides into Monday: what to watch as Taiwan trading reopens

UMC shares resume trading in Taipei Monday after falling 8.77% Friday; U.S.-listed shares dropped 3.9%. Investors await January sales data on Feb. 5 for signs of demand and pricing. The company projects first-quarter wafer shipments steady, gross margins in the high-20% range, and 2026 capital spending at $1.5 billion. Capacity utilization is expected in the mid-70% range.
2 February 2026
·
UMC stock jumps 10% toward a fresh high ahead of United Microelectronics earnings

UMC stock jumps 10% toward a fresh high ahead of United Microelectronics earnings

UMC’s U.S.-listed shares surged about 10% Tuesday, touching a 52-week high of $12.68 before settling near $12.46 in New York trading. No immediate company news explained the move, with attention turning to Wednesday’s quarterly earnings. The jump followed a broader rally in chip stocks and record highs in U.S. markets. UMC’s earnings call is scheduled for Jan. 28.
27 January 2026
····
100 Semiconductor Giants Powering the Modern World

100 Semiconductor Giants Powering the Modern World

Samsung Electronics regained the top spot in global semiconductor revenue in 2024 at $66.5 billion. TSMC controls about 61% of foundry revenues, while NVIDIA leads fabless chip sales with $124.3 billion. ASML remains the sole supplier of EUV lithography machines. Synopsys and Cadence together hold 74% of the EDA market.
22 June 2025
···········

Stock Market Today

  • Soligenix Publishes HyBryte Clinical Data Validating Safety and Efficacy
    March 19, 2026, 2:04 PM EDT. Soligenix (NASDAQ: SNGX), a biopharmaceutical firm targeting rare diseases, reported the publication of clinical trial data on HyBryte (synthetic hypericin) in the peer-reviewed journal Expert Opinion on Investigational Drugs. The summary underscores HyBryte's safety profile, non-mutagenic mechanism, and demonstrated efficacy against cutaneous T-cell lymphoma (CTCL). The data supports HyBryte's potential as a first-line treatment. Soligenix continues its ongoing FLASH2 Phase 3 trial for HyBryte, with an interim analysis slated for Q2 2026. The company focuses on rare disease therapies and vaccine programs underpinned by proprietary technology. This publication bolsters investor confidence as Soligenix advances regulatory efforts toward global commercialization of HyBryte, expanding its pipeline across inflammatory and infectious diseases.
Go toTop